Goldman Sachs is buying a commercial real estate firm for up to $410 million
The deal includes $260 million upfront and up to $150 million more tied to performance targets, with about 80% paid in stock
Colgate-Palmolive's stock dipped by 2.35% on Tuesday following its Investor Day 2026 presentation. Analysts from various brokerages offered differing opinions on the stock's future performance. Goldman Sachs maintained a Neutral rating, predicting a potential 1% rise from the current price of Rs 1,965. Motilal Oswal upgraded its stance to Buy, projecting a 27% increase to Rs 2,500, while Nuvama also recommended a Buy, with a target price of Rs 2,350 and a potential 22.5% gain.
Nuvama highlighted the company's commitment to expanding the oral care category in India, noting that over 45% of rural and 76% of urban Indians still lack consistent oral hygiene practices. Colgate's management emphasized their focus on driving growth ahead of profitability, with the premium toothpaste segment expanding 2.5 times since 2021 and retail coverage reaching 1.7 million outlets.
Written by urgent.news from The Economic Times - Top News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Colgate-Palmolive shares fall over 2% after Investor Day. What Goldman Sachs and other brokerages are saying economictimes.indiatimes.com
- Goldman Sachs to buy real estate investment firm for $410M bankingdive.com
